Johnson & Johnson (J&J) has agreed to pay $132 per share to acquire Intra-Cellular Therapies Inc. in a deal valued at about $14.6 billion, taking ownership of Caplyta (lumateperone), a once-daily oral ...

NDA submitted to U.S. FDA for CAPLYTA® as adjunctive treatment for major depressive disorder; if approved, CAPLYTA® has ...

Johnson & Johnson acquires Intra-Cellular Therapies for $14.6 billion. The biggest driver was the rights Caplyta which has ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

Shares of Lululemon Athletica Inc. ( LULU-Q +0.65% ) were higher by 0.9 per cent on Monday after it raised its ...

Clearwater Analytics ("Clearwater") and Enfusion, Inc. ("Enfusion") today announced their entry into a definitive merger agreement for Clearwater to acquire Enfusion, a leader in software-as-a-service ...

Amazon this week is providing record low prices on multiple models of the iPad mini 7, starting at $399.00 for the 128GB ...

With a lack of competition and policy intervention by upper levels of government, Food Banks Mississauga revealed that by ...

Dagmara Genda interviews artist Vera Kox about her current exhibition ‘Sentient Soil’ at Konschthal Esch in Luxembourg ...

We recently published a list of the Top 10 Small Cap Stocks to Buy with the Highest Upside Potential. In this article, we are ...

D-Wave is a strong buy in the quantum computing market, with a first-mover advantage and promising revenue forecasts. Read ...

Our Top PicksMost Trusted NameADT Home SecurityADT is a pioneer in home security with highly customizable wireless and ...